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Abstract
Background: We investigated dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) contrast
enhancement kinetic variables quantified from normal breast parenchyma for association with presence of
breast cancer, in a case-control study.
Methods: Under a Health Insurance Portability and Accountability Act compliant and Institutional Review
Board-approved protocol, DCE-MRI scans of the contralateral breasts of 51 patients with cancer and 51 controls
(matched by age and year of MRI) with biopsy-proven benign lesions were retrospectively analyzed. Applying
fully automated computer algorithms on pre-contrast and multiple post-contrast MR sequences, two contrast
enhancement kinetic variables, wash-in slope and signal enhancement ratio, were quantified from normal parenchyma of
the contralateral breasts of both patients with cancer and controls. Conditional logistic regression was employed to assess
association between these two measures and presence of breast cancer, with adjustment for other imaging factors
including mammographic breast density and MRI background parenchymal enhancement (BPE). The area under the
receiver operating characteristic curve (AUC) was used to assess the ability of the kinetic measures to distinguish patients
with cancer from controls.
Results: When both kinetic measures were included in conditional logistic regression analysis, the odds ratio for breast
cancer was 1.7 (95 % CI 1.1, 2.8; p = 0.017) for wash-in slope variance and 3.5 (95 % CI 1.2, 9.9; p = 0.019) for
signal enhancement ratio volume, respectively. These odds ratios were similar on respective univariate analysis,
and remained significant after adjustment for menopausal status, family history, and mammographic density.
While percent BPE was associated with an odds ratio of 3.1 (95 % CI 1.2, 7.9; p = 0.018), in multivariable analysis
of the three measures, percent BPE was non-significant (p = 0.897) and the two kinetics measures remained
significant. For the differentiation of patients with cancer and controls, the unadjusted AUC was 0.71 using
a combination of the two measures, which significantly (p = 0.005) outperformed either measure alone
(AUC = 0.65 for wash-in slope variance and 0.63 for signal enhancement ratio volume).
Conclusions: Kinetic measures of wash-in slope and signal enhancement ratio quantified from normal parenchyma in
DCE-MRI are jointly associated with presence of breast cancer, even after adjustment for mammographic density and BPE.
Keywords: Breast cancer, Breast MRI, Normal parenchyma, Quantitative analysis, Contrast enhancement kinetics, Wash-in
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Background
Breast magnetic resonance imaging (MRI) is recommended
by the American Cancer Society as an adjunct to mammog-
raphy for screening women who are at high risk of develop-
ing breast cancer [1]. Mammography is limited by low
sensitivity and dense tissue can mask cancer detection
[2]. In standard breast MRI protocols, dynamic contrast-
enhanced MRI (DCE-MRI) using a gadolinium-based con-
trast agent provides a high intensity distinction between
normal and diseased breast tissue, making it sensitive to
breast tissue composition and microvascularity [3]. While
mammographic breast density has been established as an
independent risk factor [4–6], recent studies showed that
MRI background parenchymal enhancement (BPE), visu-
ally assessed by the Breast Imaging-Reporting and Data
System (BI-RADS) categories [7], is also associated with
breast cancer risk [8, 9]. BPE represents the contrast en-
hancement of fibroglandular tissue in response to the MR
contrast agent, and is typically assessed from a single se-
quence, namely the first post-contrast sequence, usually
acquired at 90 seconds (k-space center time) after contrast
agent administration [8, 9].
Breast DCE-MRI includes multiple (e.g., three) post-
contrast sequences acquired at different time points after
the injection of MR contrast agent [10]. The time-signal
intensity curves of multiple post-contrast sequences
reflect dynamic signal intensity changes induced by uptake
of contrast agent over time, and can be described by con-
trast enhancement kinetics [11]. Typical kinetic curves are
categorized at the voxel level as “persistent”, “plateau”, and
“washout” [7]. Studies have shown that the kinetic curves
of breast lesions have clinical diagnostic value for malig-
nancy (wash-out curve) and benign (persistent curve)
[11–13]. A set of common kinetic variables, such as
wash-in slope, wash-out slope, time to peak, and peak
enhancement, have been derived from the kinetic curves to
specify characteristics of temporal contrast enhancement
[14, 15], and have been associated with genetic estimates of
breast cancer recurrence risk [16] and neoadjuvant
chemotherapy response [17]. Other empirical variables
of enhancement kinetics, such as the signal enhance-
ment ratio (SER) computed based upon an early and a
delayed post-contrast MR sequence, have also been derived
as an imaging biomarker and shown useful for predicting
benignity/malignancy [18] and breast tumor response to
chemotherapy [10].
In addition to characterizing breast lesions, contrast
enhancement kinetics computed from normal breast
parenchyma (i.e., fibroglandular tissue) may capture certain
physiologic/biologic characteristics of the breast as well.
Contrast enhancement features involving both normal
parenchyma and breast lesion have been shown indicative
of breast tumor molecular subtypes [19]. A recent study
showed a difference in the kinetic features of normal breast
tissue between BRCA1/2 mutation carriers and matched
non-BRCA high-risk patients [20]. The kinetic variables
derived from normal breast parenchyma are likely related
to the risk of developing breast cancer. The purpose of this
study was to investigate association between automatically
computed quantitative contrast enhancement kinetics of




This retrospective study was compliant with the Health
Insurance Portability and Accountability Act (HIPAA)
and received Institutional Review Board (IRB) approval
by the University of Pittsburgh, Human Research Protec-
tion Office (HRPO). Patient consent was waived. In a case-
control setting this study included 102 women identified
from an existing original research study. The original study
had a separate IRB aimed at comparing the diagnostic
performance of breast MRI, breast tomosynthesis, and
computed tomography in women with known breast ab-
normalities, detected in a diagnostic setting by digital mam-
mography, ultrasound, and/or clinical exam from January
2009 to December 2011 at our institution. Exclusion
criteria were history of breast cancer, breast implants,
lactating, benign breast surgery within one year, or
ineligibility for breast MRI. A total of 154 women were
recruited who had suspicious breast abnormalities and
were rated as BI-RADS 4 or 5. These women con-
sented to undergo bilateral breast MRI examinations
before undergoing a percutaneous core and/or surgical
biopsy. For premenopausal women, MRI was ideally
scheduled the second week of the menstrual cycle but
the actual date of MRI and date of onset of last men-
strual period were recorded. Of the 154 women,
pathological assessment confirmed 65 breast cancer
cases and 89 benign lesions after MRI. In the present
study MRI scans were assessed in 51 cases of unilat-
eral cancer, excluding 14 cases of incomplete DCE
subtraction sequences (missing due to informatics fail-
ure in archiving image scans). We implemented a
case-control design with individual matching, control-
ling for unmeasured variability in factors associated
with patients (by matching for age) and MRI tech-
niques (by matching for year of MRI). Using a 1:1 ra-
tio, 51 controls were selected from the 89 patients
with unilateral biopsy-proven benign lesions, individu-
ally matched to patients with cancer by age (±3 years)
and year of MRI (±1 year). Control status was affirmed
by medical record review showing no diagnosis of
breast cancer, with an average 3.7 years follow up
(range 1.4–5.5 years). A total of 102 breast DCE-MRI
scans were analyzed in this study.
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MRI protocols
MRI was performed at our institution using a standard
and consistent clinical breast MRI protocol. Women
were imaged in the prone position by a 1.5 T scanner
(GE Signa EXCITE, GE Health, Nutley, NJ, USA)
using a dedicated 7-channel surface array breast coil
(InVivo, Gainesville, FL, USA). Imaging parameters
were: matrix 512 × 512; slice thickness 2 mm; field of
view 28–34 cm, flip angle 10°, repetition time (TR)
5.68 msec, echo time (TE) 2.736 msec. Bolus injection
of the contrast agent, ProHance (Bracco Diagnostics,
Princeton, NJ, USA), at 0.1 mmol/kg, 3 cc/sec was
followed by a 20-cc saline flush. The first post-
contrast sequence acquisition was centered at 90 sec-
onds after contrast agent injection. A pre-contrast se-
quence and three sequential time point post-contrast
sequences were acquired in the axial view for bilateral
breasts, where each sequence took approximately 3 -
minutes to complete, depending on field of view sizes
selected to cover the breasts. Three subtraction se-
quences (SUB1, SUB2, and SUB3) were generated by
subtracting the pre-contrast sequence from each of
the three post-contrast sequences, respectively, as part
of routine post-processing with CADstream (Merge
Healthcare Inc., Chicago, IL, USA).
Kinetic variable quantification
Previously published automated computer algorithms
[21–23] were employed to process breast DCE-MRI scans
and quantify contrast kinetics (Fig. 1). Kinetic variables
were generated breast-wise from the contralateral breasts
of patients with cancer and controls. Standard kinetic vari-
ables of wash-in slope, wash-out lope, time to peak, peak
enhancement, and SER [10, 14], were computed based on
the pre-contrast and three post-contrast sequences (see
the references for their mathematical definitions and illus-
trations). Details of the automated process are briefly de-
scribed in the next two paragraphs.
First, the whole breast region was outlined from breast
MR images [21] and the fibroglandular tissue contents
were segmented over the whole breast region [22] (Fig. 1a).
The segmentation masks of breast and fibroglandular
tissue were translated to all three sequential subtraction
sequences after rigid inter-sequence registration (Fig. 1b-d).
For each voxel belonging to the fibroglandular tissue, voxel-
wise values for each of the four kinetic variables (wash-in
slope, wash-out slope, time to peak, and peak enhance-
ment) were computed. Then the mean and variance of the
voxel-wise kinetic values were calculated for each kinetic
variable, generating eight kinetic measures in total.
Preliminary univariate analyses of the eight kinetic
Fig. 1 Automated measurement of contrast enhancement kinetic variables from normal parenchyma. a Automated segmentation of breasts (red
contour) and fibroglandular tissue (green contour) from pre-contrast sequences. b The first time point subtraction (i.e., post-contrast–pre-contrast)
sequence with superimposed segmentation. c The second time point subtraction sequence. d The third time point subtraction sequence. e Background
parenchymal enhancement (BPE) (color-coded voxels in purple) quantified from the first time point subtraction (SUB) sequence. f Illustration of
signal enhancement ratio (SER) quantification. The kinetics of each voxel was color-coded, based on the defined range of the voxel-wise SER
values (see [10, 18]), as persistent (blue), plateau (yellow), or washout (red). SER volume is calculated as the total volume of voxels having SER ≥0.9 (i.e.,
those voxels that have either plateau or washout kinetics). g Calculation of wash-in slope from peak enhancement and time to peak, for each voxel of
fibroglandular tissue; here peak enhancement and time to peak were identified voxel-wise through all three sequential subtraction sequences
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measures showed that the variance of wash-in slope
values (denoted by wash-in slope variance, Fig. 1g) is
most likely to be associated with presence of breast
cancer [24], and therefore, we chose to focus on exam-
ining the effect of wash-in slope variance.
Second, the SER was computed for each voxel over
the fibroglandular tissue by:
SER ¼ S1‐S0ð Þ= S3‐S0ð Þ ¼ SUB1=SUB3;
where S0, S1, and S3 are signal intensities of the same
voxel in the pre-contrast, first post-contrast, and third
post-contrast images, respectively [10]. Based on the range
of voxel-wise SER values with respect to the persistent,
plateau, and washout kinetics defined in previous breast
MRI studies [18], and referring to a preliminary evaluation
[25], we chose to test a volumetric measure (denoted by
SER volume, unit: cm3) defined as the total volume of
enhancing voxels having SER ≥0.9 (i.e., those voxels that
have either plateau or washout kinetics; Fig. 1f).
For comparison purposes, MRI BPE was also quantified
from DCE-MRI (Fig. 1e). BPE contains voxels that had at
least 20 % enhancement on the signal intensities of the first
post-contrast image relative to the corresponding pre-
contrast image, referring to a previously published method
[23]. The percentage of the volume of BPE over breast
volume was derived and denoted as BPE%. Standard clinical
assessment of mammographic density by BI-RADS breast
density categories was retrieved from mammography re-
ports of the digital mammograms acquired within 6 months
prior to the analyzed MRI scans.
Statistical analysis
The primary analysis compared the two kinetic measures
(wash-in slope variance and SER volume) in the contralat-
eral breasts of patients with cancer and controls. We first
examined the odds ratios for breast cancer of the kinetic
measures using univariate and multivariate conditional
logistic regression, where the multivariate regression was
controlled for three base factors: menopausal status (pre-
menopausal or postmenopausal), family history of breast
cancer, and BI-RADS-based mammographic density cat-
egories. Family history of breast cancer was encoded as
binary (positive if at least one first, second, or third-degree
family member was diagnosed with breast cancer). Ability
of kinetic measures to distinguish patients with cancer
from controls was also assessed using area under the
receiver operating characteristic (ROC) curve (AUC) from
unconditional logistic regression models. The likelihood
ratio test was used to assess differences in the AUC. Ef-
fects of BPE% were also tested by univariate and multivari-
able logistic regression, and ROC analysis. All statistical
tests were two-sided, with p < 0.05 considered statistically
significant. Statistical analyses were performed using SAS
software (version 9.3 SAS Institute, Cary, NC, USA).
Results
Patient and imaging characteristics
Table 1 summarizes characteristics of the study cohort
and imaging measures. Based on mammography and/or
ultrasound, 40 (78 %) of the 51 breasts studied in
patients with cancer were classified as BI-RADS 5, and
47 (92 %) of the 51 breasts studied in controls with
benign lesions were classified as BI-RADS 4. The four
control group patients with a diagnostic BI-RADS 5
lesion and a benign result on percutaneous biopsy
underwent confirmatory excisional biopsy to resolve
the discrepancy between the radiological findings and
the percutaneous biopsy pathological findings, and all
four lesions were verified to be benign. The vast majority,
i.e., 46 (90 %) of patients with cancer and of controls, were
reported as BI-RADS 1 or 2 for the contralateral breast,
and no malignancies were found at biopsy in those rated
BI-RADS 4 for the contralateral breast (4 women in each
of the cancer and control groups).
The 51 cancer cases primarily involved invasive cancers,
including 26 invasive ductal carcinoma (IDC), four inva-
sive lobular carcinoma (ILC), one invasive mixed ductal-
lobular carcinoma, 18 mixed IDC and ductal carcinoma in
situ (DCIS), and two DCIS. Of the 49 invasive cancers, 37
were estrogen receptor (ER)-positive or progesterone
receptor (PR)-positive, including 9 that were positive for
human epidermal growth factor receptor 2 (HER2); 10
were ER-negative and PR-negative (including 9 that were
triple negative); and 2 were missing receptor status.
Tumor size measured 2 cm or less in 18 patients, 2–5 cm
in 31 patients, and more than 5 cm in 2 patients, with a
median size of 2.4 cm.
There were 24 matched pairs of premenopausal women
and 17 matched pairs of postmenopausal women. Ten pairs
were discordant for menopausal status because the primary
matching was age (±3 years), not menopausal status. This
resulted in four premenopausal cases having postmeno-
pausal controls, and six postmenopausal cases having pre-
menopausal controls. A total of 58 women from the full
cohort were premenopausal, and of these, MRI was not
performed in 15 women in each of the cancer and control
groups during the second week of the menstrual cycle.
Biopsies had been performed on either one or both breasts
in those who had undergone prior biopsy. The rate of
family history of breast cancer was similar in cases (51 %)
and controls (61 %). Of note, six patients with cancer had
additional risk factors (family history of ovarian cancer,
BRCA1/2 mutations, or prior atypia), compared to none in
the control group. The use of an exogenous hormone was a
mixture of current and past use, with the majority being
past use (e.g., 76 % and 88 % of women in the cancer and
Wu et al. Breast Cancer Research  (2016) 18:76 Page 4 of 10
control groups, respectively, had used birth control pills in
the past). No patients in the study cohort had taken aroma-
tase inhibitors.
Spearman’s correlation coefficients (SCC) showed mod-
erate correlation with BPE% for each of wash-in slope
variance (SCC = 0.56, p < 0.0001) and SER volume (SCC =
0.48, p < 0.0001), but these two kinetic measures were not
correlated with each other (SCC = 0.17, p = 0.1). Wash-in
slope variance (SCC = -0.18, p = 0.07) and SER volume
(SCC = -0.21, p = 0.03) were both weakly negatively
correlated with the established risk factor, mammo-
graphic density.
Association between kinetic measures and presence of
breast cancer
In univariate analysis, ordinal mammographic density
categories did not predict case/control status in this cohort
(p > 0.45), while BPE% showed an association, with an odds
Table 1 Patient and imaging characteristics of the 102 patients including 51 breast cancer cases and 51 matched controls with
biopsy-proven benign lesions
Patient/imaging characteristics Cancer cases (n = 51) Controls (n = 51)
Diagnostic BI-RADS findings in single-side breast on mammography and/or ultrasound
Breast with lesion (cancer/benign) BI-RADS 4 11 (22 %) 47 (92 %)
BI-RADS 5 40 (78 %) 4 (8 %)
Contralateral (studied) breast BI-RADS 1 27 (53 %) 21 (41 %)
BI-RADS 2 19 (37 %) 25 (49 %)
BI-RADS 3 1 (2 %) 1 (2 %)
BI-RADS 4 4 (8 %) 4 (8 %)
BI-RADS 5 0 (0 %) 0 (0 %)
Age, years, mean ± SD (range) 47.6 ± 7.4 (34–60) 47.1 ± 7.3 (31–60)
Menopausal status
Premenopausal 28 (55 %) 30 (59 %)
Postmenopausal 23 (45 %) 21 (41 %)
Known pathogenic BRCA1/2 mutation 2 (4 %) 0 (0 %)
History of prior breast cancer 0 (0 %) 0 (0 %)
Family history of breast cancer 26 (51 %) 31 (61 %)
Family history of ovarian cancer 3 (6 %) 0 (0 %)
Prior biopsy (>1 year prior to the studied biopsy)
Atypia 1 (2 %) 0 (0 %)
Benign abnormality 9 (18 %) 6 (12 %)
Exogenous hormone use
Hormone replacement therapy 7 (14 %) 5 (10 %)
Birth control pills 33 (65 %) 34 (67 %)
Tamoxifen 1 (2 %) 0 (0 %)
None 5 (10 %) 12 (24 %)
Oophorectomy 0 (0 %) 0 (0 %)
Mammographic density (visual BI-RADS density description)
Fatty 2 (4 %) 1 (2 %)
Scattered fibroglandular density 14 (27 %) 13 (25 %)
Heterogeneously dense 32 (63 %) 33 (65 %)
Extremely dense 3 (6 %) 4 (8 %)
Background parenchymal enhancement, BPE%, mean ± SD (range) 44.6 ± 8.9 (20.9–62.0) 39.8 ± 11.4 (17.9–61.6)
Kinetics imaging measures, mean ± SD (range)
Wash-in slope variance × 100 (unit) 2.90 ± 2.72 (0.48–15.42) 1.75 ± 1.26 (0.43–6.87)
Signal enhancement ratio volume, cm3 118.9 ± 85.6 (26.1–429.8) 80.4 ± 42.9 (21.1–194.5)
Data are numbers of subjects, with percentages in parentheses, unless stated otherwise. BI-RADS Breast Imaging-Reporting and Data System
Wu et al. Breast Cancer Research  (2016) 18:76 Page 5 of 10
ratio = 3.1 (95 % CI 1.2, 7.9), p = 0.018. Figure 2 shows
comparisons of the MRI measures for the matched pairs.
For both the two kinetic variables and BPE%, higher values
occur more frequently in cases compared to matched
controls. BPE% was at least 15 % higher in patients with
cancer as compared to controls in over half of the matched
pairs. For wash-in slope variance, 33 (65 %), 13 (25 %), and
5 (10 %) patients with cancer had values that were >15 %
greater than, >15 % less than, and within 15 % of the corre-
sponding values in the matched controls, respectively. For
SER volume, 31 (61 %), 15 (29 %), and 5 (10 %) patients
with cancer cases had values that were >15 % greater
than, >15 % less than, and within 15 % of the corre-
sponding values in matched controls, respectively. An
example is shown in Fig. 3 for selected representative
slices of two MRI scans illustrating differences in the two
kinetic variables between cancer cases and controls.
Table 2 shows the results of univariate and multivari-
ate conditional logistic regression analyses of the associ-
ation between case-control status and the two kinetic
measures and BPE%. The odds of malignancy were 1.7
times greater for each unit increase in wash-in slope
variance (95 % CI 1.1, 2.7), and 3.1 times greater for each
100 cm3 increase SER volume (95 % CI 1.3, 7.5). These
odds ratios remained very similar in models including
both of the kinetic measures, even after adjustment for
additional base risk factors (menopausal status, family
history of breast cancer, and ordinal mammographic
density) or the measure of BPE%. While univariate ana-
lysis showed a significant association (p = 0.018) between
BPE% and cancer-control status, we noted that BPE%
became non-significant (p = 0.897), and the two kinetics
measures remained significant, when the three measures
were jointly included in multivariate analysis. In addition,
when excluding the six pairs in whom the patients with
cancer (cases) had additional risk factors as described
above, wash-in slope variance maintained a very similar
association (p < 0.05) but association of SER became mar-
ginal (p > 0.056), after adjusting for the base factors or
BPE%. The same phenomena for the two variables were
observed when the 10 pairs mismatched for menopausal
status were excluded from analysis.
Preliminary performance of kinetic variables in
classification
Unconditional logistic regression models were fitted to
estimate the AUC for kinetic variables and BPE% as
breast cancer screening classifiers (Table 3). Prediction of
malignancy was significantly superior when both wash-in
slope variance and SER volume were included in the regres-
sion model, compared to including either measure alone
(both p = 0.005). The unadjusted (i.e., no cross-validation)
and leave-one-out cross-validated AUC for a model with
both variables as predictors was 0.71 and 0.68, respectively.
When BPE% was added to the combination of the two
kinetic variables, the unadjusted AUC was only margin-
ally greater (AUC = 0.72) than without BPE% (AUC =
0.71), p = 0.775.
Discussion
In this study, DCE-MRI contrast enhancement kinetic
variables quantified from normal breast parenchyma were
Fig. 2 Kinetic variable and background parenchymal enhancement (BPE) comparisons between pairs of contralateral breasts in patients with
cancer (cases) and controls matched by age and year of magnetic resonance imaging. Dots represent values of the measured kinetic variables or
BPE%. Line colors encode differences between cases and controls as a percentage of the measure for controls. Red lines indicate pairs where the
case value is >15 % greater than the control. Blue lines indicate pairs where the case value is >15 % less than the control. Black lines indicate pairs
where the case value is within 15 % of the control value. This figure shows a trend of higher values measured in cancer cases compared to the matched
controls for the two kinetic variables, wash-in slope variance (left) and signal enhancement ratio volume (middle), and the measure of BPE% (right)
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investigated in a case-control setting and were found to be
associated with presence of breast cancer. Essentially, the
measure of wash-in slope variance captures a form of
voxel-wise heterogeneity of contrast uptake/enhancement
in normal parenchyma, and the measure of signal en-
hancement ratio volume reflects the absolute amount of
breast parenchyma that has a mixture of voxels with
washout or plateau kinetics. To the best of our knowledge,
this is the first study that quantitatively assessed MRI
contrast enhancement kinetics of normal parenchyma for
studying associations with the presence of breast cancer.
We showed that these two kinetics measures were jointly
associated with the presence of breast cancer, indicating
that they may convey complementary breast-cancer-related
information. The associations were maintained even after
adjusting for mammographic density and BPE%. BPE has
been previously shown to be associated with breast cancer
risk [8, 9] and it was also associated with the presence of
breast cancer in this study. Our results suggest that the
identified association between the presence of breast cancer
and the two kinetic measures may extend to prediction of
breast cancer risk.
Breast cancer is a biologically heterogeneous disease [26].
While the BI-RADS-category-based BPE assessment [8, 9]
and the quantitative BPE% in this work characterize pri-
marily the "amount" information on enhanced background
Fig. 3 Selected representative slices of two magnetic resonance imaging (MRI) scans showing difference in the two kinetic variables between
cancer cases and controls. Row 1 is for a 58-year old postmenopausal woman with cancer (mixed invasive ductal carcinoma and ductal carcinoma
in situ); row 2 is for a 57-year old postmenopausal woman from the control group, who had a biopsy-proven benign lesion. In all plots, red contours
outline the breast area and green contours outline the fibroglandular tissue. Left column (a, d) fibroglandular tissue segmentation. Middle column (b, e)
color-coded voxels with a signal enhancement ratio (SER) value > =0.9 (red for washout kinetics having SER >1.3 and yellow for plateau kinetics having
0.9 < =SER < =1.3). These colored voxels on all slices were accumulated to compute SER volume (138.9 cm3 for the cancer case vs 102.0 cm3 for the
controls). Right column (c, f) color-coded wash-in slope values. The color bar is for the two rightmost plots (c, f) only, denoting the range of the wash-in
slope values. Wash-in slope variance (0.04 for the cancer case vs 0.01 for the control) was computed based on the wash-in slope values of color-coded
voxels on all slices. SUB subtraction
Table 2 Odds ratios for breast cancer computed by univariate and multivariate conditional logistic regression analyses on the
contralateral breasts of patients with cancer and controls (n = 102, 51 women with a cancer diagnosis and 51 controls with benign
biopsy, matched by age and year of magnetic resonance imaging)
Conditional logistic
regression models
Variables included in conditional logistic regression analyses
Wash-in slope variance (WISV) (unit) Signal enhancement ratio volume (SERV) (cm3) BPE% (%)
OR (95 % CI); p value OR (95 % CI); p value OR (95 % CI); p value
WISV univariate 1.7 (1.1, 2.7); p = 0.014 - -
SERV univariate - 3.1 (1.3, 7.5); p = 0.014 -
WISV + SERV 1.7 (1.1, 2.8); p = 0.017 3.5 (1.2, 9.9); p = 0.019 -
Base factors +WISV + SERVa 1.8 (1.1, 2.9); p = 0.020 3.7 (1.2, 11.2); p = 0.020 -
BPE% univariate - - 3.1 (1.2, 7.9); p = 0.018
WISV + SERV + BPE% 1.7 (1.1, 2.8); p = 0.024 3.4 (1.1, 10.6); p = 0.038 1.1 (0.3, 3.8); p = 0.897
Odds ratio (OR) for WISV is per 0.01-unit difference. OR for SERV is per 100-cm3 difference. OR for percentage background parenchymal enhancement relative to
breast volume (BPE%) is per 20 % point difference. aBase factors = menopausal status (premenopausal vs postmenopausal), family history of breast cancer (yes/no,
first to third degree family member), and Breast Imaging-Reporting and Data System (BI-RADS)-based mammographic density categories
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parenchyma, the kinetic variables reflect some information
on the voxel-wise heterogeneity in the abnormal contrast
enhancement occurring in breast parenchyma that are still
normal. The abnormal enhancement/vascularity character-
istics may represent certain biological progression of poten-
tial disease development. Thus, compared to BPE, the
kinetic variables are expected to capture some more rele-
vant breast tissue profiles in relation to breast cancer risk.
While both kinetic variables were correlated with BPE%,
they remained as independent predictors of the presence of
breast cancer, even after adjusting for BPE% in multivariate
logistic regression analyses. However, future larger risk-
assessment studies are warranted to further evaluate the
value of DCE-MRI kinetics in prediction of breast cancer
risk. While the kinetics of lesions have been used in the
clinic for breast cancer diagnosis [11], the tested kinetic
variables derived from normal parenchyma are expected to
contribute to the estimation of breast cancer risk in the
context of breast MRI screening. In this study, the MRI
scans examined for the contralateral breasts of the patients
with cancer were those obtained in patients with a current
cancer diagnosis. It may be that contralateral breast kinetics
and BPE% measured on women with known cancer in the
other breast were actually elevated secondarily to the
presence of the cancer. This case-control study impli-
cates contralateral breast kinetic variables as markers of
the presence of cancer, and we hypothesize that these
may predict the development of breast cancer as well.
To test this hypothesis, we plan to perform a follow up
study using normal MRI scans acquired prior to diagnosis
of cancer to further investigate the association between
DCE-MRI kinetic variables and breast cancer risk.
In the context of breast cancer screening, existing risk
models underestimate observed rates of breast cancer at
the population level and are only moderate accurate at
the individual level [27, 28]; for example, the AUC of the
Gail, Claus, and Tyrer-Cuzick models is approximately
0.735, 0.716, and 0.762, respectively [29]. The ultimate
goal of identifying new and significant imaging risk fac-
tors from quantitative breast MRI assessment would be
to improve risk assessment accuracy and better guide in-
dividual decisions for more aggressive screening [30].
This study showed that the combination of two MRI
kinetics measures alone yielded an AUC of 0.71, which
is comparable to those of current risk models, although
this is only a preliminary evaluation. We note that because
the cases and controls in this study were matched by some
risk factors (e.g., age) and not others (e.g., family history),
our study precluded assessment of the incremental value of
the kinetic variables over existing breast risk factors
[31–33]. In future work, larger studies are warranted to
fully examine the effect of incorporating the kinetic vari-
ables as potential risk biomarkers into current risk models.
Kinetic assessment of normal breast parenchyma has
been shown to be related to the phase of the menstrual
cycle in premenopausal women [34, 35]. About half of
the 58 premenopausal women in our study had their MRI
examinations outside the clinically recommended scan-
ning window (i.e., second week of the menstrual cycle), 15
each for cases and controls. A recent study suggested that
kinetic parameters of breast parenchyma were elevated
when measured outside of the recommended interval, in
patients with benign but not malignant lesions [35]. If that
is the case, we would expect the measured DCE-MRI
kinetics outside the second week in the 15 women with
benign lesions in our control group to be higher than the
actual levels. In the case-control analysis this would at-
tenuate the effect of the kinetic measures between cancer
and control groups. Despite this attenuation effect, we still
found an association between breast DCE-MRI kinetics
and presence of breast cancer.
There are several other limitations to our work. In this
single-institution retrospective study, the sample size is
relatively small and the MRI scans are consistent in the
imaging protocol and parameters; thus generalizability of
our results remains to be validated by a larger dataset,
ideally in a multicenter study. Given the preliminary nature
of this study mainly for generating hypotheses, multi-test
correction was not applied and we believe the proof-of-
concept results will be valuable in guiding study design and
Table 3 Area under the receiver operating characteristic curve (AUC) for differentiation between patients with cancer and controls,
analyzed by unconditional logistic regression models






P value (likelihood ratio test)
M1 Wash-in slope variance (WISV) univariate 0.65 (0.54, 0.76) 0.61 (0.49, 0.72) -
M2 Signal enhancement ratio volume (SERV) univariate 0.63 (0.52, 0.74) 0.59 (0.48, 0.70) -
M3 WISV + SERV 0.71 (0.61, 0.81) 0.68 (0.58, 0.79) M3 vs M1: 0.005
M3 vs M2: 0.005
M4 BPE% univariate 0.64 (0.53, 0.75) 0.60 (0.49, 0.72) -
M5 WISV + SERV + BPE% 0.72 (0.62, 0.82) 0.66 (0.56, 0.77) M5 vs M3: 0.775
M5 vs M4: 0.004
BPE% percentage of background parenchymal enhancement volume relative to breast volume
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appropriate power calculations for larger studies. In
addition, in the contralateral breasts of both patients
with cancer and controls, there were some benign results
(e.g., BI-RADS 2), which on one hand showed the robust-
ness of the association of kinetics derived from a wider
range of normal breast tissue, and on the other hand may
have introduced bias by including benign findings in quan-
tifying kinetics. Finally, kinetics of the normal parenchyma
in the ipsilateral side of patients with breast cancer may
merit investigation as well, but such an analysis remains for
future work, as our current computer algorithms lack the
function of separating normal parenchyma from breast
tumor in cancer-affected breasts.
Conclusions
In summary, breast DCE-MRI kinetic variables derived
from normal breast parenchyma are associated with the
presence of breast cancer, potentially independent of mam-
mographic density and MRI BPE. In this study we reported
fully automated computerized methods for quantifying
kinetics. Such an approach is essential for conducting large
quantitative studies and can accelerate the translational use
of reproducible imaging biomarkers in the clinic. Our
results support further investigation of quantitative DCE-
MRI kinetics from normal parenchyma as a potential new
risk biomarker aimed at ultimately improving prediction
and management of breast cancer risk [36–38]
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